Canaccord Genuity Maintains $39.0 Target Price On Genomic Health (GHDX), Maintains “Buy” Rating; Walter & Keenan Financial Consulting Company Lowered Merck & Co (MRK) Position

November 15, 2017 - By wolcottdaily

Among 8 analysts covering Genomic Health (NASDAQ:GHDX), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Genomic Health has $44 highest and $25 lowest target. $33’s average target is 16.44% above currents $28.34 stock price. Genomic Health had 24 analyst reports since August 5, 2015 according to SRatingsIntel. Raymond James upgraded the stock to “Market Perform” rating in Friday, August 28 report. Canaccord Genuity maintained Genomic Health, Inc. (NASDAQ:GHDX) on Monday, September 25 with “Buy” rating. The rating was maintained by Jefferies on Wednesday, August 17 with “Hold”. The firm has “Hold” rating by Jefferies given on Tuesday, September 12. The rating was maintained by Jefferies on Friday, October 20 with “Hold”. Cowen & Co upgraded Genomic Health, Inc. (NASDAQ:GHDX) on Thursday, November 19 to “Outperform” rating. The stock of Genomic Health, Inc. (NASDAQ:GHDX) has “Buy” rating given on Wednesday, January 6 by Canaccord Genuity. On Wednesday, November 4 the stock rating was upgraded by Raymond James to “Outperform”. The rating was downgraded by Piper Jaffray on Monday, January 11 to “Neutral”. On Wednesday, September 2 the stock rating was initiated by Barclays Capital with “Underweight”.

Walter & Keenan Financial Consulting Company decreased Merck & Co Inc (MRK) stake by 12.81% reported in 2017Q2 SEC filing. Walter & Keenan Financial Consulting Company sold 5,288 shares as Merck & Co Inc (MRK)’s stock declined 2.46%. The Walter & Keenan Financial Consulting Company holds 35,982 shares with $2.31 million value, down from 41,270 last quarter. Merck & Co Inc now has $148.72B valuation. The stock declined 0.84% or $0.46 reaching $54.53 per share. About 902,929 shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 16.86% since November 15, 2016 and is uptrending. It has outperformed by 0.16% the S&P500.

Investors sentiment increased to 1.66 in Q2 2017. Its up 0.56, from 1.1 in 2017Q1. It improved, as 6 investors sold Genomic Health, Inc. shares while 32 reduced holdings. 11 funds opened positions while 52 raised stakes. 30.55 million shares or 1.09% more from 30.22 million shares in 2017Q1 were reported. State Bank Of Mellon Corporation reported 89,714 shares. Swiss Fincl Bank reported 0% stake. Legal & General Group Public Ltd stated it has 6,932 shares. Eagle Asset Management owns 379,473 shares. Minnesota-based Us Savings Bank De has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). Independent Portfolio Consultants Inc reported 0.22% in Genomic Health, Inc. (NASDAQ:GHDX). State Farm Mutual Automobile Insur Com, Illinois-based fund reported 317,240 shares. 8,622 are owned by Voya Invest Limited. Bogle Invest Management Limited Partnership De, a Massachusetts-based fund reported 60,541 shares. Bnp Paribas Arbitrage Sa owns 2,396 shares. Invesco holds 0% or 203,149 shares. Morgan Stanley stated it has 53,942 shares or 0% of all its holdings. Aqr Mgmt Ltd Llc accumulated 65,892 shares. 15,857 were reported by Manufacturers Life The. Ameritas Invest Prtnrs holds 0% or 1,734 shares.

Since May 16, 2017, it had 0 buys, and 3 insider sales for $466,905 activity. Cole G Bradley sold 5,000 shares worth $158,342. Shares for $161,582 were sold by Popovits Kimberly J. Shak Steven sold 5,000 shares worth $146,981. 8,250 Genomic Health, Inc. (NASDAQ:GHDX) shares with value of $243,745 were sold by Cohen Fred E.

Analysts await Genomic Health, Inc. (NASDAQ:GHDX) to report earnings on February, 13. They expect $0.09 earnings per share, up 125.00% or $0.05 from last year’s $0.04 per share. GHDX’s profit will be $3.13M for 78.72 P/E if the $0.09 EPS becomes a reality. After $0.03 actual earnings per share reported by Genomic Health, Inc. for the previous quarter, Wall Street now forecasts 200.00% EPS growth.

About 2,103 shares traded. Genomic Health, Inc. (NASDAQ:GHDX) has risen 23.46% since November 15, 2016 and is uptrending. It has outperformed by 6.76% the S&P500.

Genomic Health, Inc. is a healthcare firm that provides genomic diagnostic tests to personalize cancer treatment. The company has market cap of $985.99 million. The Firm develops and commercializes genomic clinical laboratory services. It currently has negative earnings. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Investors sentiment increased to 1.07 in 2017 Q2. Its up 0.08, from 0.99 in 2017Q1. It increased, as 56 investors sold MRK shares while 612 reduced holdings. 111 funds opened positions while 603 raised stakes. 1.95 billion shares or 0.77% less from 1.96 billion shares in 2017Q1 were reported. Strategic Wealth Llc holds 71,634 shares or 0.66% of its portfolio. Piedmont Inv Limited Co has invested 1.03% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Hartford Investment Mgmt has 627,001 shares. Torch Wealth Management Lc has invested 1.2% in Merck & Co., Inc. (NYSE:MRK). Systematic Mngmt Lp invested in 0.14% or 118,114 shares. Ghp Invest holds 25,476 shares. Southeast Asset Advsr Inc has invested 0.11% in Merck & Co., Inc. (NYSE:MRK). Fifth Third Bancshares accumulated 808,025 shares or 0.38% of the stock. Tdam Usa Incorporated stated it has 0.55% in Merck & Co., Inc. (NYSE:MRK). Rnc Cap Mgmt Ltd Liability Corporation reported 15,675 shares or 0.08% of all its holdings. Homrich & Berg has 27,861 shares. Loomis Sayles & Communication Lp has invested 0.88% in Merck & Co., Inc. (NYSE:MRK). Princeton Port Strategies Grp invested in 103,449 shares or 1.9% of the stock. Paloma Prns Mgmt holds 0.07% or 94,708 shares. Palladium holds 84,785 shares or 0.43% of its portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :